Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.

Antineoplastic Combined Chemotherapy Protocols / therapeutic use Cladribine / therapeutic use Cytarabine / therapeutic use Humans Leukemia, Myeloid, Acute / diagnosis Neoplasm, Residual Prognosis Remission Induction Salvage Therapy
Acute myeloid leukemia hematopoietic stem cell transplant minimal residual disease relapsed/refractory leukemia salvage chemotherapy

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 22 9 2020
medline: 28 4 2021
entrez: 21 9 2020
Statut: ppublish

Résumé

We compared the outcomes of salvage chemotherapy in 146 patients with relapsed (57.5%) or refractory (42.5%) AML who received CLAG-M (51%), MEC (39%) or CLAG (10%). Minimal residual disease (MRD) was assessed by flow cytometry. Bivariate, Kaplan-Meier, and Cox regression analyses were conducted. Complete remission (CR) rate of 46% (CLAG-M 54% versus MEC/CLAG 40%,

Identifiants

DOI: 10.1080/10428194.2020.1821009 PMID: 32951486
pubmed: 32951486
doi: 10.1080/10428194.2020.1821009
doi:

Substances chimiques

Cytarabine 04079A1RDZ
Cladribine 47M74X9YT5

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

158-166

Subventions

Organisme : NCI NIH HHS
ID : P30 CA014520
Pays : United States

Auteurs

Muhammad Umair Mushtaq (MU)

Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
ORCID: 0000-0001-8122-0563

Alexandra M Harrington (AM)

Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.

Sibgha Gull Chaudhary (SG)

Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Laura C Michaelis (LC)

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Karen-Sue B Carlson (KB)

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Sameem Abedin (S)

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Lyndsey Runass (L)

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Natalie S Callander (NS)

Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Michael J Fallon (MJ)

University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Mark Juckett (M)

Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Aric C Hall (AC)

Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Peiman Hematti (P)

Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Ryan J Mattison (RJ)

Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Ehab L Atallah (EL)

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Guru Subramanian Guru Murthy (GS)

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Comparison of salvage chemotherapy regimens...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Ribonucléosides › Adénosine › Chloro-2 adénosine › Chloro-2 désoxyadénosine › Comparison of salvage chemotherapy regimens...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Cytarabine › Comparison of salvage chemotherapy regimens...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Comparison of salvage chemotherapy regimens...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Comparison of salvage chemotherapy regimens...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Maladie résiduelle › Comparison of salvage chemotherapy regimens...
questionsmedicales.fr › Diagnostic › Pronostic › Comparison of salvage chemotherapy regimens...
questionsmedicales.fr › Thérapeutique › Induction de rémission › Comparison of salvage chemotherapy regimens...
questionsmedicales.fr › Thérapeutique › Thérapie de rattrapage › Comparison of salvage chemotherapy regimens...